Educating Stakeholders and Preparing for Bispecific Antibodies Across Lymphoma Indications

Effective integration of bispecific antibodies in follicular lymphoma relies on comprehensive education for both patients and healthcare providers. Patients benefit from clear explanations about therapy mechanisms, administration schedules, potential adverse events, and strategies for self-monitoring, empowering them to engage actively in their care. Concurrently, educating healthcare providers—including physicians, nurses, and pharmacists—ensures familiarity with dosing protocols, toxicity management, and workflow coordination. As bispecific antibodies expand into early-line treatment for diffuse large B-cell lymphoma (DLBCL), operational considerations such as infusion scheduling, monitoring for cytokine release syndrome and neurotoxicity, and resource allocation become increasingly critical. Multidisciplinary collaboration and proactive planning are essential to manage these challenges effectively. By fostering education and preparedness across all stakeholders, healthcare teams can optimize safety, efficacy, and patient experience, setting the stage for successful adoption of bispecific therapies across lymphoma subtypes.